Introduction of BPaL-L, a 6-month RR-TB regimen.

Introduction of BPaL-L, a 6-month RR-TB regimen.

Introduction of BPaL-L, a 6-month RR-TB regimen.

Objectives: 

South Africa has been a global leader in introducing innovation to the field of Rifampicin-resistant tuberculosis (RR-TB) and the work done in the country has had a significant impact on global policy. One of these innovations are the implementation of clinical access programmes for Bedaquiline, followed by Delamanid and BPaL.

This webinar will discuss the implementation and roll-out of this new six-month BPaL-L RR-TB regimen.

Discuss NDOH plan for introduction of BPaL-L.


Discuss major changes to RR-TB guidelines regarding: diagnosis, eligibility criteria for treatment, treatment regimen, patients’ follow-up.

Speakers: 

Prof Norbert Ndjeka 
Chief Director: TB Control and Management Cluster (NDoH) 
Qualifications: MD, DHSM (Wits), MMed (Fam Med) (MED), Dip HIV Man (CMSA), DSc (h.c.) 

Dr Francesca Conradie
Deputy Executive Director: Wits Health Consortium
Qualifications: MBChB

Dr Lindiwe Mvusi
Director DS-TB (NDoH) 
Qualifications: MBChB


Video: 

New DR TB Regimen 30 August 2023

 

Date
30 August 2023 - 02:00 pm
until
30 August 2023 - 03:30 pm
CPD points
2
Type
Medical
Topic
TB